NOVO HEAL, INC.

Biotech

Anti-fibrotic therapeutic treatment for vocal fold injury that inhibits TGF-β1–driven fibrosis to restore vocal fold micro-architecture

Grants
$305K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · STTR Phase I: Anti-scarring Therapies for Vocal Fold Injury$305,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1392CYNVEC, LLC—$500K
1393Infinite Elements, Inc.——
1394NEONC TECHNOLOGIES INC—$394K
1395NOVO HEAL, INC.——
13963RT INNOVATIONS——
1397Granite Bio——
1398Emalex Biosciences——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.